Skip Main Navigation Links Jump to Footer
International Journal of CancerVolume 135, Issue 2, 15 July 2014, Pages 253-263

The network of P-glycoprotein and microRNAs interactions(Review)(Open Access)

  • aCancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
  • bCenter of Medicinal Chemistry, University of Porto, CEQUIMED-UP, Porto, Portugal
  • cInstitute of Biomedical Sciences Abel Salazar, University of Porto, ICBAS-UP, Porto, Portugal
  • dDepartment of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal
  • eDepartment of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

Abstract

Overexpression of P-glycoprotein (P-gp) contributes to the multidrug resistance (MDR) phenotype found in many cancer cells. P-gp has been identified as a promising molecular target, although attempts to find successful therapies to counteract its function as a drug efflux pump have largely failed to date. Apart from its role in drug efflux, P-gp may have other cellular functions such as being involved in apoptosis, and is found in various locations in the cell. Its expression is highly regulated, namely by microRNAs (miRNAs or miRs). In addition, P-gp may regulate the expression of miRs in the cell. Furthermore, both P-gp and miRs may be found in microvesicles or exosomes and may be transported to neighboring, drug-sensitive cells. Here, we review this current issue together with recent evidence of this network of interactions between P-gp and miRs. © 2013 UICC.

Author keywords

cancerdrug resistanceexosomesmicroRNAsmicrovesiclesP-glycoprotein

Indexed keywords

EMTREE drug terms:messenger RNAmultidrug resistance protein
EMTREE medical terms:binding affinitybinding sitecancer resistancecellular distributiondown regulationexosomegene expressiongene functiongene identificationgene locationhumanmicrovasculaturemolecular dynamicsnonhumanpriority journalprotein determinationprotein expressionprotein functionprotein localizationprotein RNA bindingprotein synthesisprotein transportreviewRNA transcriptionRNA transportsignal transduction
Medline keywords:cancerdrug resistanceexosomesmicroRNAsmicrovesiclesP-glycoprotein
MeSH:AnimalsDrug Resistance, MultipleDrug Resistance, NeoplasmGene Expression RegulationHumansMicroRNAsP-GlycoproteinSignal Transduction

Chemicals and CAS Registry Numbers:

multidrug resistance protein, 149200-37-3, 208997-77-7

Funding details

Funding sponsor Funding number Acronym
Office of Fuel Cycle TechnologiesSFRH/BD/47428/2008FCT
Office of Fuel Cycle TechnologiesSFRH/BD/87646/2012FCT
Office of Fuel Cycle TechnologiesSFRH/BPD/68787/2010FCT
  • ISSN: 00207136
  • CODEN: IJCNA
  • Source Type: Journal
  • Original language: English
  • DOI: 10.1002/ijc.28500
  • PubMed ID: 24122334
  • Document Type: Review
  • Publisher: Wiley-Liss Inc.

  Vasconcelos, M.H.; IPATIMUP, Institute of Molecular Pathology and Immunology, University of Porto, Rua Dr. Roberto Frias s/n, Portugal;
© Copyright 2014 Elsevier B.V., All rights reserved.

Cited by 36 documents

Gawel, A.M. , Godlewska, M. , Grech-Baran, M.
MIX2: A Novel Natural Multi-Component Modulator of Multidrug-Resistance and Hallmarks of Cancer Cells
(2019) Nutrition and Cancer
Zhou, Y. , Wang, M. , Shuang, T.
MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional repressor
(2019) Pathology Research and Practice
Lo Re, G. , Lo Re, F. , Doretto, P.
Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience
(2019) Cytokine
View details of all 36 citations
{"topic":{"name":"Urinary Bladder Neoplasms; Cells; Cancer cells","id":61488,"uri":"Topic/61488","prominencePercentile":30.594204,"prominencePercentileString":"30.594","overallScholarlyOutput":0},"dig":"b6bdbe24752d92d48e9807a568c91b7d71ae2709daf50a0430e9022557014287"}

SciVal Topic Prominence

Topic:
Prominence percentile: